Tianjin Chase Sun Pharmaceutical Co.,Ltd

XSEC:300026 Stock Report

Market Cap: CN¥12.0b

Tianjin Chase Sun PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

Tianjin Chase Sun PharmaceuticalLtd's earnings have been declining at an average annual rate of -0.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.1% per year. Tianjin Chase Sun PharmaceuticalLtd's return on equity is 2%, and it has net margins of 2.9%.

Key information

-0.1%

Earnings growth rate

-0.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate2.1%
Return on equity2.0%
Net Margin2.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tianjin Chase Sun PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300026 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,6271662,436210
30 Jun 245,6823092,390203
31 Mar 245,9133892,450204
31 Dec 236,1095072,515210
30 Sep 236,6726632,826209
30 Jun 236,7626172,971220
31 Mar 236,5775612,859229
01 Jan 236,6506242,807231
30 Sep 227,0845213,026257
30 Jun 227,4966023,099231
31 Mar 227,7647323,133207
31 Dec 217,6716873,128197
30 Sep 217,2666112,837197
30 Jun 217,1926672,846198
31 Mar 217,0016572,811195
31 Dec 206,4885732,717177
30 Sep 206,1094852,708161
30 Jun 205,4973962,565161
31 Mar 205,0853372,553174
31 Dec 195,0034032,534179
30 Sep 194,7962642,513166
30 Jun 194,5482162,412161
31 Mar 194,3032192,267143
31 Dec 184,2242112,210141
30 Sep 184,0154632,016126
30 Jun 183,8945141,876161
31 Mar 183,6054851,713134
31 Dec 173,3744511,618109
30 Sep 173,5436331,69470
30 Jun 173,5646301,8180
31 Mar 173,7436661,9820
31 Dec 163,8676592,1000
30 Sep 163,7225822,2110
30 Jun 163,6355992,1950
31 Mar 163,5965722,2370
31 Dec 153,3485352,1530
30 Sep 153,1875411,9880
30 Jun 153,0764741,9610
31 Mar 152,9694521,9220
31 Dec 142,8644471,8600
30 Sep 142,6814211,7560
30 Jun 142,4053951,5620
31 Mar 142,2013621,4180
31 Dec 132,0973401,3490

Quality Earnings: 300026 has a large one-off gain of CN¥143.3M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300026's current net profit margins (2.9%) are lower than last year (9.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300026's earnings have declined by 0.1% per year over the past 5 years.

Accelerating Growth: 300026's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300026 had negative earnings growth (-75%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 300026's Return on Equity (2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies